G.I. Research Institute

Summary

G.I. Research Institute is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Inflammatory Bowel Disease, Chronic Hepatitis B and other specialties. G.I. Research Institute is involved with conducting 89 clinical trials across 64 conditions. There are 4 research doctors associated with this hospital, such as Gregory Rosenfeld, Hin Hin Ko, MD, Alnoor Ramji, MD, and Brian Bressler, MD.

Top PIs

Clinical Trials running at G.I. Research Institute

Crohn's Disease

Liver Fibrosis

Ulcerative Colitis

Alpha-1 Antitrypsin Deficiency

Inflammatory Bowel Disease

Eosinophilic Esophagitis

Fatty Liver Disease

Colonic Polyps

Colon Lesions

Colon Polyps

Gut Microbiome Analysis

for Crohn's Disease

The goal of this prospective observational study is to determine if specific microbiome signatures can predict therapeutic responses in adult patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD), living in British Columbia, Canada. The main questions this study seeks to answer are: 1. Can microbiome signatures across different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) predict response to therapy in CD? 2. How do microbiome profiles differ between active and quiescent CD and non-IBD controls? Researchers will compare microbiome signatures in patients with active and inactive CD as well as non-IBD controls to see if there are any microbial signatures that predict response to therapy. Participants will: 1. Provide fecal and blood samples. 2. Undergo intestinal washings and intestinal epithelial biopsy specimens taken during routine colonoscopy. 3. Participate in a longitudinal follow-up over 12 months to monitor clinical, biochemical, and endoscopic responses to therapy.

Recruiting

1 award

N/A

10 criteria

TAK-279

for Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

Recruiting

0 awards

Phase 2

Icotrokinra

for Crohn's Disease

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

Recruiting

0 awards

Phase 2 & 3

4 criteria